Journal
RHEUMATOLOGY
Volume 57, Issue 11, Pages 1885-1895Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kex391
Keywords
IL-6; rheumatoid arthritis; tocilizumab; sarilumab; sirukumab
Categories
Funding
- Sanofi Genzyme
- Regeneron Pharmaceuticals, Inc.
Ask authors/readers for more resources
RA is a chronic, systemic, autoimmune disease characterized by inflammation and degradation of the joints, causing significant negative impact on quality of life. In addition to joint disease, symptoms and comorbidities associated with RA-namely pain, fatigue and mood disorders-are often as debilitating as the disease itself. The pro-inflammatory cytokine IL-6 plays a critical role in RA-associated pathology. However, a greater understanding of the translational effects of IL-6 outside of the immune system is needed. This review discusses our current understanding of emerging aspects of IL-6 in RA-associated pain, fatigue and mood disorders such as depression and anxiety. This review also describes the clinical effects of IL-6 inhibition on these symptoms and co-morbidities in patients with RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available